Aileron Therapeutics, Inc. (NASDAQ:ALRN) Expected to Announce Earnings of -$0.09 Per Share

Brokerages predict that Aileron Therapeutics, Inc. (NASDAQ:ALRNGet Rating) will report earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics reported earnings of ($0.06) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 50%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Aileron Therapeutics will report full year earnings of ($0.38) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.37). For the next year, analysts forecast that the firm will report earnings of ($0.39) per share, with EPS estimates ranging from ($0.39) to ($0.38). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRNGet Rating) last announced its earnings results on Thursday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01).

Several analysts have issued reports on ALRN shares. William Blair reaffirmed an “outperform” rating on shares of Aileron Therapeutics in a research report on Tuesday, March 29th. Zacks Investment Research lowered shares of Aileron Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Aileron Therapeutics in a research report on Friday, May 20th.

ALRN traded down $0.01 during trading hours on Thursday, hitting $0.44. 39,885 shares of the company’s stock were exchanged, compared to its average volume of 329,151. Aileron Therapeutics has a 1-year low of $0.32 and a 1-year high of $1.40. The stock’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.49. The stock has a market cap of $39.51 million, a price-to-earnings ratio of -1.45 and a beta of 2.50.

Several institutional investors and hedge funds have recently modified their holdings of ALRN. KCK LTD. bought a new position in shares of Aileron Therapeutics in the fourth quarter valued at about $362,000. Blair William & Co. IL raised its position in shares of Aileron Therapeutics by 32.9% in the fourth quarter. Blair William & Co. IL now owns 1,067,489 shares of the company’s stock valued at $601,000 after purchasing an additional 264,329 shares during the period. Bailard Inc. bought a new position in shares of Aileron Therapeutics in the first quarter valued at about $66,000. Acadian Asset Management LLC bought a new position in shares of Aileron Therapeutics in the fourth quarter valued at about $47,000. Finally, Envestnet Asset Management Inc. raised its position in shares of Aileron Therapeutics by 152.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 136,760 shares of the company’s stock valued at $77,000 after purchasing an additional 82,584 shares during the period. 37.06% of the stock is currently owned by institutional investors.

Aileron Therapeutics Company Profile (Get Rating)

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.

Recommended Stories

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Want More Great Investing Ideas?

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.